The oxytocin levels were significantly lower in patients with than in those without MS (8.65±2.69 vs. 10.87±5.93 ng/L, respectively), while the irisin levels were comparable in the two groups (p=0.049 and p=0.104, respectively). This evidence concerns the gene FNDC5 and myeloid sarcoma.